Fueling chimeric antigen receptor T cells with cytokines

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T therapy has revolutionized hematological malignancy treatment.
• Significant challenges persist, including limited CAR-T cell proliferation, persistence, trafficking, and overcoming the suppressive tumor microenvironment (TME).

Purpose of the Study:

• To review the critical role of cytokines in enhancing CAR-T cell anti-tumor activity.
• To explore how cytokine modification facilitates the clinical translation of CAR-T therapies.

Main Methods:

• Literature review of pre-clinical models and clinical trials.
• Analysis of cytokine families, chemokines, and their receptors in CAR-T cell function.
• Examination of immunosuppressive molecules and pro-inflammatory cytokines impacting CAR-T efficacy.

Main Results:

• Cytokine 'armoring' of CAR-T cells demonstrably strengthens anti-tumor responses.
• Specific cytokines, such as those from the common γ-chain family, are key promoters of CAR-T cell function.
• Chemokines and chemokine receptors influence CAR-T cell trafficking and infiltration into tumors.

Conclusions:

• Cytokines are pivotal in overcoming CAR-T therapy limitations, enhancing proliferation, persistence, and tumor infiltration.
• Strategic use of cytokines offers a promising avenue to improve CAR-T cell efficacy and clinical success in cancer treatment.